Skip to main content
OpenTrials
Completed

NCT Number: NCT04809207

Acceptability, Feasibility and Preliminary Efficacy of CFWP to Treat Clinically Elevated Fatigue in Adults With CF

This research is being done to learn more ways to treat non-respiratory symptoms in people with CF including fatigue, pain, mood, sleep problems and the use of a wellness program to treat them.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cystic Fibrosis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Fatigue Genetic Diseases, Inborn Infant, Newborn, Diseases Lung Diseases Pancreatic Diseases Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Johns Hopkins University, Baltimore, Maryland, United States

Loading trial locations.

About this study

This study aims to test the acceptability, feasibility and preliminary efficacy of a tailored intervention known as the CF Wellness Program (CFWP) to treat clinically elevated fatigue in adults with CF. This is a pre-post pilot intervention study of the CF-Wellness Program. This study is needed because fatigue negatively affects health-related quality of life and has been identified by those with CF as a symptom that needs to be addressed. The study will include approximately 50 participants and the intervention will last approximately 13 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥18 years old
  • Documentation of CF diagnosis in the medical record
  • If prescribed a modulator (i.e., ivacaftor, lumacaftor/ivacaftor, tezacaftor/ivacaftor, & elexacaftor/tezacaftor/ivacaftor), have been on treatment for at least 4 weeks
  • If prescribed medicine for psychiatric purpose, must be on treatment for at least 8 weeks
  • Has access to a smartphone, tablet, and/or computer with access to internet
  • Ability to understand/read/speak English
  • Receives CF care at a participating CF Center
  • Has a score of >4 on the Fatigue Severity Scale
  • Not likely to start and/or change modulator treatments during the intervention period

Exclusion criteria

  • Receiving antibiotic treatment for a pulmonary exacerbation 14 days prior to the screening or expected to start within 14 days after screening visit
  • Is pregnant or less than 6 months postpartum (self-reported)
  • Is currently participating in another interventional trial
  • Contraindication for aerobic exercise (determined by treating physician including cardiovascular, pulmonary and/or musculoskeletal contraindications)
  • Forced Expiratory Volume in 1 second percent predicted (FEV1pp) is <25% within last year
  • Planning to transfer care to a non-participating CF Center before the post-intervention visit could be completed
  • Will not be available to complete CF-Wellness sessions in a timely fashion (e.g., will be on extended travel)
  • Has already participated in the CF Wellness Program

Treatment and study plan

CF Wellness Program Sessions

Other

The intervention will last approximately 12 weeks. During this time, up to 9 coaching sessions will be delivered. Each will last approximately 45 - 60 minutes. Sessions will be delivered either by web-based video chat (e.g., Zoom) or by telephone. Sessions will cover content such as understanding the physiological, cognitive, affective, behavioral contributors to CF fatigue; understanding the role of physical activity/exercise and fatigue including the importance of balancing activity and rest periods; cognitive restructuring; addressing attention and interpretation processes contributing to fatigue; teaching techniques such as mindfulness meditation relaxation strategies, good sleep hygiene, and activity scheduling and behavioral activation; and engaging social support. Physical activity goals will be set each session. Participants will be encouraged to use the provided fitness tracker and to sync weekly prior the coaching session so that the results can inform session content.

Primary outcomes

  1. Proportion enrolled in the CF Wellness Program (CFWP)

    Time frame: Day 0

    Number of participants enrolled into the CFWP Intervention among those eligible.

  2. Proportion of cognitive behavioral therapy (CBT) sessions completed

    Time frame: At approximately 13 weeks post intervention

    Mean of the number of completed cognitive behavioral therapy (CBT) sessions divided by the number of sessions expected per participant.

  3. Proportion of weeks participant synced the fitness tracker watch to the Smartphone app

    Time frame: At approximately 13 weeks post intervention

    This will be measured as the mean of the number of syncs completed divided by the number expected per participant. The fitness tracker watch with smartphone app data will be used to assess the proportion of weeks participant synced the fitness tracker watch to the Smartphone app.

Secondary outcomes

  1. Feasibility of the CF Wellness Program as assessed by the Intervention Feasibility and Acceptability questionnaire (iFAQ) for patients

    Time frame: At approximately 13 weeks post intervention

    This measure will be used to evaluate feasibility of the intervention program. This measure will include questions about the feasibility of the program and will be assessed by the 5 point Likert Scale: Strongly disagree, Disagree, Neither Agree or Disagree, Agree, Strongly Agree.

    The scores will be averaged within participants to get a total score and then across participants; a mean score of 4 on a 5-point scale will be considered high satisfaction with the intervention.

  2. Acceptability of the CF Wellness Program as assessed by the Intervention Feasibility and Acceptability questionnaire (iFAQ) for patients

    Time frame: At approximately 13 weeks post intervention

    This measure will be used to evaluate acceptability of the intervention program. This measure will be assessed by the 5 point Likert Scale: Strongly disagree, Disagree, Neither Agree or Disagree, Agree, Strongly Agree.

    The scores will be averaged within participants to get a total score and then across participants; a mean score of 4 on a 5-point scale will be considered high satisfaction with the intervention.

  3. Qualitative interview as assessed by thematic analysis

    Time frame: At approximately 13 weeks post intervention

    A semi-structured interview will be conducted by the research team about the CF Wellness Program overall, and each module specifically, to determine the participants' perceptions of the degree to which the intervention was engaging, feasible, acceptable and useful. Recommendations for improving the CF Wellness Program will be solicited. The interviews will be recorded and their transcripts will be thematically analyzed using Nvivo Statistical & Qualitative Data Analysis Software.

  4. Mean change in fatigue as assessed by the Functional Assessment of Chronic Illness-Fatigue ( FACIT-F) Scale

    Time frame: Day 1 to approximately 13 weeks post intervention

    The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) is a measure that assesses self-reported fatigue and its impact upon daily activities and function. The scale is a 13-item, easy to administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The total scores will be calculated and a score greater than 36 will indicate elevated fatigue.

  5. Change in exercise capacity as assessed by the 1 Minute Sit to Stand Test (1MSTST) test and Fitness tracker watch

    Time frame: Day 1 to approximately 13 weeks post intervention

    The 1 Minute Sit to Stand Test (1MSTST) test is used to assess exercise capacity and leg muscle strength. The participants are required to rise from a chair with their arms across their chest as often as possible in one minute. The number of chair rises will be calculated.

    The heart rate recovery (HRR) will be captured after the 1MSTST. The participant will wear a fitness tracker that will track heart rate. The heart rate peak will be calculated as the mean heart rate The fitness tracker watch will also be used to track the average 7 day daily step count of the study participants in order to determine if there are changes in their activity levels throughout the intervention program.

  6. Change self-reported sleep disturbance as assessed by the Pittsburgh Sleep Quality Index (PSQI)

    Time frame: Day 1 to approximately 13 weeks post intervention

    This measures sleep disturbance and usual sleep habits during the prior month. The Pittsburgh Sleep Quality Scale (PSQI) is a 19-item self-rated questionnaire for evaluating subjective sleep quality the previous month. The 19 questions are combined into 7 clinically-derived component scores, each weighted equally from 0-3. The 7 component scores are added to obtain a global score ranging from 0-21, with higher scores indicating worse sleep quality.

  7. Change in self-reported pain as assessed by the Patient-Reported Outcome Measurement Information System (PROMIS) Pain Intensity scale

    Time frame: Day 1 to approximately 13 weeks post intervention

    The PROMIS(r) Pain Intensity instrument assesses how much a person hurts. The items in the Pain Intensity scale assess pain intensity utilizing a 7-day recall period (items include the phrase "the past 7 days") while the last item asks patient to rate their pain intensity "right now. Each item is rated on a scale ranging from 1 (had no pain) to 5 (very severe). A higher total score, indicates severe pain level.

  8. Change in self-reported depression as assessed by the Patient Health Questionnaire Depression Scale (PHQ-8)

    Time frame: Day 1 to approximately 13 weeks post intervention

    This is a measure used for assessing and monitoring depression severity. The PHQ-8 is an eight item self-reported measure of depression. Each item is rated on a scale ranging from 0 (not at all) to 3 (nearly every day). Total score is the sum of individual eight items and ranges from 0 to 24, with higher scores indicating more severe depression symptoms. Total score of 0 to 5 indicates none to minimal depression, 6 to 10 indicates mild depression, 11 to 15 indicates moderate depression, 16 to 20 indicates moderately severe depression and 21 to 24 indicates severe depression.

  9. Change in self-reported anxiety as assessed by the General Anxiety Disorder - 7 (GAD7) scale

    Time frame: Day 1 to approximately 13 weeks post intervention

    This is a measure initially developed to diagnose generalized anxiety disorder. The GAD-7 is a seven item, self-reported measurement of GAD severity. Each item is rated on a scale ranging from 0 (not at all) to 3 (nearly every day). Total score is the sum of individual seven items and ranges from 0 to 21, with higher scores indicating more severe anxiety symptoms. Total score of 0 to 5 indicates none to minimal anxiety, 6 to 10 indicates mild anxiety, 11 to 15 indicates moderate anxiety, 16 to 21 indicates severe anxiety.

Sponsors and collaborators

Lead sponsor

Johns Hopkins University

Other

Collaborators

  • Cystic Fibrosis Foundation
  • University of Washington

Registry information

Official study title

The CF Wellness Program to Treat Fatigue

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Mar 22, 2021
Registry last updated
Aug 28, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.